WASHINGTON, D.C., June 5, 2026
Altesa BioSciences has unveiled encouraging new Phase 2 clinical findings demonstrating that vapendavir, its investigational oral antiviral therapy, significantly reduced viral load and inflammatory responses in chronic obstructive pulmonary disease (COPD) patients infected with rhinovirus. The results, presented at the 2026 American Society for Microbiology (ASM) Microbe Conference, further strengthen the scientific rationale for targeting respiratory viral infections as a strategy to prevent COPD exacerbations. As rhinovirus is responsible for approximately 50% of acute COPD flare-ups, the findings highlight the potential of vapendavir to address a major unmet need in respiratory medicine. Currently, there are no approved therapies or vaccines specifically targeting rhinovirus infections, making vapendavir one of the most closely watched investigational treatments in this field. The data arrive as Altesa advances its multinational Phase 2b CARDINAL study, designed to evaluate whether antiviral intervention can reduce illness severity, improve respiratory symptoms, and preserve lung function in vulnerable COPD patients.
Phase 2 Findings Demonstrate Reduced Viral Burden and Inflammation
The newly presented challenge study evaluated the biological impact of vapendavir in COPD patients experimentally infected with rhinovirus. Researchers observed that treatment with the oral antiviral significantly reduced inflammatory mediators commonly associated with viral infection and COPD exacerbation severity. Compared with placebo, vapendavir lowered peak IFN-α2a levels by approximately 38%, reduced IP-10 levels by nearly 50%, and decreased IL-29 levels by approximately 67%. These biomarkers play critical roles in antiviral immune responses and inflammatory signaling pathways that contribute to respiratory symptom burden and lung injury during viral infections.
Investigators also reported reductions in viral load, supporting the drug’s mechanism of action as a rhinovirus capsid inhibitor that blocks viral entry into human cells and prevents viral replication. The findings suggest that vapendavir may not only reduce the intensity of infection but could also lessen the inflammatory cascade that drives acute COPD exacerbations, which remain a leading cause of hospitalization, accelerated lung function decline, and mortality among patients living with chronic respiratory disease.
Targeting Rhinovirus Could Transform COPD Management
Advertisement
COPD affects hundreds of millions of individuals worldwide and is among the leading causes of death globally. Despite advances in inhaled therapies and disease management, viral respiratory infections continue to trigger a substantial proportion of acute exacerbations. Rhinovirus, the most common viral cause of the common cold, has emerged as a particularly important contributor to disease worsening in COPD patients. Vapendavir was specifically designed as a broad-spectrum oral antiviral agent with activity against approximately 97% of rhinovirus strains and other respiratory enteroviruses. Unlike conventional COPD therapies that primarily focus on symptom management and airway inflammation, vapendavir directly targets the underlying infectious trigger responsible for many disease flare-ups.
Researchers believe this approach could represent a paradigm shift in respiratory medicine by treating the root cause of exacerbations rather than simply managing their consequences. The oral formulation also provides practical advantages for outpatient treatment and early intervention, potentially reducing healthcare utilization and improving quality of life for patients at high risk of recurrent respiratory complications.
CARDINAL Trial Advances Next Phase of Clinical Development
Building on the positive Phase 2 findings, Altesa recently initiated patient enrollment in the Phase 2b CARDINAL clinical trial, a multinational randomized placebo-controlled study expected to enroll approximately 900 COPD patients across the United States and United Kingdom. Participants who develop rhinovirus infections during monitoring will be randomized to receive one of two vapendavir dose levels or placebo. The study’s primary objective is to evaluate improvement in respiratory symptoms, while secondary endpoints include time to symptom resolution, quality of life, healthcare resource utilization, and maintenance of lung function.
Researchers also see broader opportunities for vapendavir beyond COPD, including potential applications in asthma and other high-risk respiratory populations susceptible to severe viral infections. With no approved rhinovirus-directed treatments currently available, vapendavir represents a potentially groundbreaking antiviral strategy that could redefine the prevention and management of virus-driven COPD exacerbations, offering new hope for patients facing chronic respiratory disease and repeated hospitalizations.
Source: Altesa BioSciences press release
